Cargando…
Non-randomized therapy trial to determine the safety and efficacy of heavy ion radiotherapy in patients with non-resectable osteosarcoma
BACKGROUND: Osteosarcoma is the most common primary malignant bone tumor in children and adolescents. For effective treatment, local control of the tumor is absolutely critical, because the chances of long term survival are <10% and might effectively approach zero if a complete surgical resection...
Autores principales: | Blattmann, Claudia, Oertel, Susanne, Schulz-Ertner, Daniela, Rieken, Stefan, Haufe, Sabine, Ewerbeck, Volker, Unterberg, Andreas, Karapanagiotou-Schenkel, Irini, Combs, Stephanie E, Nikoghosyan, Anna, Bischof, Marc, Jäkel, Oliver, Huber, Peter, Kulozik, Andreas E, Debus, Jürgen |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2846886/ https://www.ncbi.nlm.nih.gov/pubmed/20226028 http://dx.doi.org/10.1186/1471-2407-10-96 |
Ejemplares similares
-
Randomised trial of proton vs. carbon ion radiation therapy in patients with chordoma of the skull base, clinical phase III study HIT-1-Study
por: Nikoghosyan, Anna V, et al.
Publicado: (2010) -
Histone deacetylase inhibition sensitizes osteosarcoma to heavy ion radiotherapy
por: Blattmann, Claudia, et al.
Publicado: (2015) -
Intensity Modulated Radiotherapy (IMRT) and Fractionated Stereotactic Radiotherapy (FSRT) for children with head-and-neck-rhabdomyosarcoma
por: Combs, Stephanie E, et al.
Publicado: (2007) -
Randomized phase II study evaluating a carbon ion boost applied after combined radiochemotherapy with temozolomide versus a proton boost after radiochemotherapy with temozolomide in patients with primary glioblastoma: The CLEOPATRA Trial
por: Combs, Stephanie E, et al.
Publicado: (2010) -
Combination of suberoylanilide hydroxamic acid with heavy ion therapy shows promising effects in infantile sarcoma cell lines
por: Oertel, Susanne, et al.
Publicado: (2011)